Search

Search Constraints

You searched for: Author/Creator Lin, Thomas S.

Search Results

1. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B‐cell lymphoma. (23rd August 2013)

2. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers. Issue 4 (9th April 2023)

3. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. (16th September 2022)

4. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. (3rd March 2019)

5. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Issue 10 (24th August 2022)

7. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Issue 12 (December 2013)

9. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Issue 22 (5th November 2018)